Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05123807 Recruiting - Ovarian Cancer Clinical Trials

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Start date: January 7, 2022
Phase: Phase 2
Study type: Interventional

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

NCT ID: NCT05123482 Recruiting - Breast Cancer Clinical Trials

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Start date: October 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

NCT ID: NCT05113368 Recruiting - Ovarian Cancer Clinical Trials

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.

NCT ID: NCT05107674 Recruiting - Gastric Cancer Clinical Trials

A Study of NX-1607 in Adults With Advanced Malignancies

Start date: September 29, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

NCT ID: NCT05104515 Recruiting - Prostate Cancer Clinical Trials

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Start date: November 1, 2021
Phase: Phase 1
Study type: Interventional

OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in patients with cancer. The Study consists of 2 parts: a dose escalation part and a dose expansion part. In the dose escalation part, up to 4 increasing doses of OVM-200 will be evaluated in small groups of cancer patients to find the recommended dose for the expansion part. The recommended dose of OVM-200 will then be given to cancer patients in the dose expansion part to confirm safety and understand how effective it is against their disease and if there are any side effects. Patients who agree to participate in the Study and pass screening will receive 3 doses of OVM-200 in total at 2-week intervals as an injection under the skin. After completing treatment with OVM-200 patients will be followed up for side effects and to monitor changes in their cancer. Patients will stay on the Study for about 6 months in total during which they will have 10 hospital visits. The Study will run at around 5 sites in the UK.

NCT ID: NCT05103683 Recruiting - Ovarian Cancer Clinical Trials

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

TRIO049
Start date: November 17, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

NCT ID: NCT05099978 Recruiting - Ovarian Cancer Clinical Trials

Asian Multicenter Prospective Study of ctDNA Sequencing

A-TRAIN
Start date: November 1, 2021
Phase:
Study type: Observational

This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions.

NCT ID: NCT05095558 Recruiting - Clinical trials for Ovarian Cancer Recurrent

Microtransplantation for Ovarian Cancer

Start date: October 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, we will apply micro transplantation to the field of recurrent and advanced ovarian cancer to study the efficacy and safety.

NCT ID: NCT05092763 Recruiting - Ovarian Cancer Clinical Trials

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer

FIT4SURGERY
Start date: December 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effectiveness of a home-based, patient-tailored intervention, FIT4SURGERY, to promote physical activity among women with ovarian cancer undergoing neoadjuvant chemotherapy.

NCT ID: NCT05086692 Recruiting - Ovarian Cancer Clinical Trials

A Beta-only IL-2 ImmunoTherapY Study

ABILITY-1
Start date: August 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.